Sanofi

Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Sanofi-aventis

Lothar Schwink

Siegfried Stengelin

Matthias Gossel

Gerhard Hessler

Petra Lennig

Heiner Glombik

Christian Buning

Thomas M Boehme

Torsten Haack

Werngard Czechtizky

Zhongli Gao

William Joseph Hurst

Dieter Kadereit

Kurt Ritter

Nis Halland

Petra Stahl

Matthias Lohmann

Christoph Pöverlein

Wendelin Frick

Stefanie Keil

Wolfgang Wendler

Eugen Falk

Gerhard Jaehne

Karl Schoenafinger

Klaus Wirth

Elisabeth Defossa

Georg Tschank

Ulrich Werner

Dirk Gretzke

Hans-Ludwig Schäfer

Holger Wagner

Thomas Klabunde

Thomas Maier

Armin Walser

Martin Bossart

Hans-Ludwig Sch&auml;fer

Daniel Dembkowski

Petra Lenning

Gunther Schmalz

David Sucunza

Janna Velder

Gerard Rosse

The present disclosure relates to azetidine compounds. The azetidine compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The present disclosure furthermore relates to the use of azetidine compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Azetidine compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Isoindolinone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

The invention relates to amino alcohol-substituted arylthienopyrimidinones having a formula I and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one amino alcohol-substituted arylthienopyrimidinone of the invention or its derivative, and the use of the amino alcohol-substituted arylthienopyrimidinones of the invention and their derivatives as MCH antagonists.

Amino alcohol-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments

The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders

Disclosed is a tetrahydronapthalene compound having Formula I the variables of which are as described herein, methods of preparing same and their use.

Substituted tetrahydronaphthalenes, method for the production thereof, and use thereof as drugs

The invention relates to azacyclyl-substituted arylthienopyrimidinones and their derivatives, of the Formula (I); and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted arylthienopyrimidinone according to Formula (I) or its derivative, and the use of the azacyclyl-substituted arylthienopyrimidinones according to Formula (I) and their derivatives as MCH antagonists.

Azacyclyl-substituted arylthienopyrimidinones, process for their preparation and their use as medicaments

The invention relates to azacyclyl-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one azacyclyl-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the azacyclyl-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists.

Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments

The present invention discloses and claims a series of substituted N-phenyl-bipyrrolidine carboxamides of formula (I). Wherein R, R, R, Rand Rare as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted N-phenyl-bipyrrolidine carboxamides and intermediates therefor.

Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof

The invention relates to substituted tetrahydronaphthalenes and derivatives thereof, and also to the physiologically compatible salts and physiologically functional derivatives thereof, to preparation thereof, to medicaments comprising at least one inventive substituted tetrahydronaphthalene or derivative thereof, and to the use of the inventive substituted tetrahydronaphthalenes and derivatives thereof as medicaments.

Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments

The invention relates to aryl-substituted polycyclic amines of formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are explained in the description, as well as to pharmaceutical compositions containing them and to methods of treatment using them.

Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament

The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane according to the invention or derivative thereof, and to the use of the substituted indanes according to the invention and to derivatives thereof as MCH antagonists.

Substituted indanes, method for the production thereof, and use thereof as drugs

The invention relates to aminoalcohol-substituted aryldihydroisoquinolinones and their derivatives, and their physiologically tolerated salts and physiologically functional derivatives, their preparation, medicaments comprising at least one aminoalcohol-substituted aryldihydroisoquinolinone of the invention or its derivative, and the use of the aminoalcohol-substituted aryldihydroisoquinolinones of the invention and their derivatives as MCH antagonists.

Aminoalcohol-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments

The invention relates to aryl-substituted polycyclic amines of the formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof; where the symbols and radicals are explained in the description as well as to pharmaceutical compositions and medical treatments employing these compounds.

Growing community of inventors

Stadtallendorf, Germany

Lothar Schwink